Skip to main content
Erschienen in: Pain and Therapy 2/2017

Open Access 01.07.2017 | Editorial

Painful Peripheral Neuropathy and Cancer

verfasst von: Panagiotis Zis, Giustino Varrassi

Erschienen in: Pain and Therapy | Ausgabe 2/2017

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Peripheral neuropathy (PN) is very prevalent in cancer patients and a leading cause of pain related to cancer. However, the underlying pathophysiological mechanisms vary significantly. Peripheral neuropathy can be a direct or an indirect complication of cancer or cancer-related treatment, or a pre-existing comorbidity not related to cancer. PN might also occur as a paraneoplastic neurological syndrome. Such syndromes are immune-mediated manifestations that usually precede the diagnosis of cancer or cancer’s relapse. Pain is very prevalent in paraneoplastic peripheral neuropathies and, therefore, merits attention.

Introduction

The term peripheral neuropathy (PN) refers to any disorder of the peripheral nervous system including single and multiple (asymmetric) mononeuropathies, symmetrical involvement of many nerves (polyneuropathy) or sole involvement of the dorsal root ganglia [1, 2].
PN is very prevalent in cancer patients; however the underlying pathophysiological mechanisms vary significantly. PN can be a direct or an indirect complication of cancer or cancer-related treatment, or a pre-existing comorbidity not related to cancer. Directly cancer can cause single or multiple mononeuropathies and plexopathy as a result of invasion by cancer cells of the peripheral nerves and plexus, respectively [3]. Indirectly, similar pathologies might occur following iatrogenic nerve and plexus injuries, either secondary to radiotherapy or surgery [4]. Treatment-related PN also includes chemotherapy-induced PN, which is probably the most common cause of PN in cancer [5].
However, PN in cancer might occur as a paraneoplastic neurological syndrome (PNS). PNS are a heterogeneous group of neurological disorders triggered by cancer. To be considered as paraneoplastic, the neurological syndrome should occur within 5 years of cancer diagnosis [6], though there are many reports of possible PNS that have exceeded this time-frame [7]. PNS are caused by mechanisms other than metastases, metabolic or nutritional deficits, infections, coagulopathy, or side effects of cancer treatment such as chemotherapy. The discovery that many PNS are associated with antibodies against neural antigens expressed by the tumour (antineural antibodies) has suggested that PNS are immune-mediated [8]. Paraneoplastic PN is one of the commonest PNS and often is a cause of neuropathic cancer pain [9].
This editorial is an introduction to an up-to-date systematic review and meta-analysis of all published case reports or case series of patients with paraneoplastic PN (doi:10.​1007/​s40122-017-0076-3). The systematic review and meta-analysis shed light onto both the clinical and neurophysiological aspects, with a particular focus on pain as a manifestation of the PNS.

Acknowledgements

No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Disclosures

Panagiotis Zis and Giustino Varrassi have nothing to disclose.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Literatur
2.
Zurück zum Zitat Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol. 2016;263(10):1903–10.CrossRefPubMed Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol. 2016;263(10):1903–10.CrossRefPubMed
4.
Zurück zum Zitat Marchettini P, Formaglio F, Lacerenza M. Iatrogenic painful neuropathic complications of surgery in cancer. Acta Anaesthesiol Scand. 2001;45(9):1090–4.CrossRefPubMed Marchettini P, Formaglio F, Lacerenza M. Iatrogenic painful neuropathic complications of surgery in cancer. Acta Anaesthesiol Scand. 2001;45(9):1090–4.CrossRefPubMed
5.
Zurück zum Zitat Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.CrossRefPubMed Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.CrossRefPubMed
6.
Zurück zum Zitat Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40.CrossRefPubMedPubMedCentral Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Zis P, Rao DG, Wagner BE, Nicholson-Goult L, Hoggard N, Hadjivassiliou M. Cerebellar ataxia and sensory ganglionopathy associated with light-chain myeloma. Cereb Ataxias. 2017;4(1):1.CrossRef Zis P, Rao DG, Wagner BE, Nicholson-Goult L, Hoggard N, Hadjivassiliou M. Cerebellar ataxia and sensory ganglionopathy associated with light-chain myeloma. Cereb Ataxias. 2017;4(1):1.CrossRef
8.
Zurück zum Zitat Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543–54.CrossRefPubMed Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543–54.CrossRefPubMed
9.
Zurück zum Zitat Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract. 2012;12(3):219–51.CrossRefPubMed Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract. 2012;12(3):219–51.CrossRefPubMed
Metadaten
Titel
Painful Peripheral Neuropathy and Cancer
verfasst von
Panagiotis Zis
Giustino Varrassi
Publikationsdatum
01.07.2017
Verlag
Springer Healthcare
Erschienen in
Pain and Therapy / Ausgabe 2/2017
Print ISSN: 2193-8237
Elektronische ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-017-0077-2

Weitere Artikel der Ausgabe 2/2017

Pain and Therapy 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.